Company intelligence / Profile preview

Neosoma

Groton, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

FDA 510(k) cleared AI-based software for neuro-oncology, providing tumor segmentation, volumetric measurements, and longitudinal tracking for high-grade gliomas with 95.5% accuracy in tumor volume measurement.

Therapeutic areas: Oncology
Industry: Medical Imaging

Partnerships

Hackensack Meridian HealthCalyxNuance Precision Imaging Network

Beyond the preview

Go deeper on Neosoma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neosoma.

Explore the full profile